BSX · Boston Scientific Corporation
$44.232026-07-21Sector: Healthcare; Industry: Medical - Devices; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$32
-26.6% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($32 · $61) Analysts Range ($55 · $120) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $14.2B | — | 18.4% | 17.6% | $2.2B | −$2.8B | −$597MM | 6.6% | — | 6.8% | $31.8B | $1.07 | — |
| 2024.Q4 | $14.2B | 0.0% | 18.4% | 19.1% | $2.1B | −$5.1B | −$3.0B | 7.8% | — | 6.3% | $35.5B | $1.07 | — |
| 2025.Q1 | $16.7B | 17.6% | 18.9% | 18.3% | $2.6B | −$5.2B | −$2.6B | 7.0% | — | 7.2% | $36.7B | $1.24 | — |
| 2025.Q4 | $16.7B | 0.0% | 18.9% | 14.6% | $2.7B | −$2.0B | $666MM | 7.7% | — | 7.2% | $38.1B | $1.24 | — |
| 2026.Q1 | $20.6B | 23.1% | 24.2% | 4.9% | $4.7B | −$2.7B | $2.0B | 6.7% | — | 12.1% | $40.4B | $2.38 | 13.3 |
| italics below = DCF projection · 10yr Rev CAGR: 7.6% |
| 2027.Q1 | $22.1B | +7.0% | 23.8% | 6.4% | $4.9B | −$2.7B | $2.3B | 7.7% | $2.1B | 11.8% | $43.1B | $2.73 | 16.2 |
| 2028.Q1 | $23.8B | +7.9% | 24.5% | 7.9% | $5.4B | −$3.3B | $2.1B | 7.8% | $1.8B | 12.0% | $46.3B | $2.99 | 14.8 |
| 2029.Q1 | $25.9B | +8.7% | 25.3% | 9.4% | $5.9B | −$4.0B | $2.0B | 7.9% | $1.6B | 12.3% | $50.3B | $3.30 | 13.4 |
| 2030.Q1 | $28.5B | +10.2% | 25.8% | 10.9% | $6.5B | −$5.6B | $925MM | 8.0% | $683MM | 12.3% | $55.9B | $3.64 | 12.2 |
| 2031.Q1 | $31.4B | +10.1% | 25.8% | 12.5% | $7.1B | −$6.4B | $703MM | 8.1% | $481MM | 12.0% | $62.3B | $3.94 | 11.2 |
|
| Term. Yr+ | $44.7B | 4.1% | 21.6% | 20.0% | $7.7B | −$3.7B | $4.1B | 8.6% | $41.3B | 8.6% | — | — | — |
Active scenario IV: $32 (-26.6% vs market)